0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes interest and refinancing burdens, giving this clinical-stage company greater financial flexibility while it funds trials. That advantage can help preserve resources for development, although it does not eliminate the need for future capital.
Clinical Pipeline ProgressCompletion of Phase 2 enrollment in EVANGELINE is a meaningful development milestone that advances the lead program toward potentially informative clinical results. Planned additional studies also broaden the pipeline and create multiple paths for future value creation.
Shareholder Participation In Voucher UpsideThe CVR structure creates a contractual mechanism for shareholders to participate in potential priority review voucher proceeds. Although payment is uncertain, it improves alignment around rare-disease development and preserves a defined source of possible future value.
Bears Say
No Commercial RevenueThe absence of commercial revenue means ATOS has no established product sales base to support operations or validate market demand. Until a candidate is approved and generates sales, financial performance will remain dependent on clinical progress and external funding.
Persistent And Rising Cash BurnIncreasing operating cash burn indicates that the company is consuming more capital as it advances its programs, while remaining unable to self-fund development. This raises the likelihood that additional financing will be needed within the coming periods.
Shrinking Equity And AssetsThe substantial decline in equity and assets reflects cumulative losses and ongoing cash usage, weakening the financial cushion available to support trials. If this trend continues, future capital raises could become increasingly important and may dilute existing shareholders.
Atossa Therapeutics News
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $24.45M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 40 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in GB:0HJ7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.